Immunotherapy of sarcomas

John M. Goldberg

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: To describe the current advances in immunotherapy and how they can be applied to sarcoma. This review will discuss the recent literature and selected clinical trials. Evidence supporting treatment with immunotherapy alone in sarcoma will be reviewed, as will the potential incorporation of immunotherapy into treatment for sarcoma. RECENT FINDINGS: Sarcoma, cancer of the connective tissues, frequently strikes young people, comprising a large percentage of cancer in children and young adults, but may occur at any age. Although molecularly targeted inhibitors are of great interest in treating sarcoma patients, immunotherapy is emerging as a plausible therapeutic modality because of the recent advances in other cancer types that may be translated to sarcoma. The licensing of ipilimumab and sipuleucel-T for cancer, and the remarkable success of immunotherapy for some childhood cancers, suggest a role for immunotherapy in the treatment of tumors like sarcoma. SUMMARY: Sarcoma is a disease for which new treatments are needed. Immunotherapies have different mechanisms of action from most current therapies and could work in concert with them. Recent advances in sarcoma biology and cancer immunotherapy suggest that our knowledge of the immune system has reached the point where it can be used to augment both targeted and multimodality therapy for sarcoma.

Original languageEnglish
Pages (from-to)390-397
Number of pages8
JournalCurrent Opinion in Oncology
Volume25
Issue number4
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Sarcoma
Immunotherapy
Neoplasms
Therapeutics
Licensure
Connective Tissue
Young Adult
Immune System
Clinical Trials

Keywords

  • antibody
  • cancer immunotherapy
  • cancer vaccines
  • dendritic cells
  • sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunotherapy of sarcomas. / Goldberg, John M.

In: Current Opinion in Oncology, Vol. 25, No. 4, 01.07.2013, p. 390-397.

Research output: Contribution to journalArticle

Goldberg, John M. / Immunotherapy of sarcomas. In: Current Opinion in Oncology. 2013 ; Vol. 25, No. 4. pp. 390-397.
@article{4d131278a6ef4fabb3e7a47c6b91969c,
title = "Immunotherapy of sarcomas",
abstract = "PURPOSE OF REVIEW: To describe the current advances in immunotherapy and how they can be applied to sarcoma. This review will discuss the recent literature and selected clinical trials. Evidence supporting treatment with immunotherapy alone in sarcoma will be reviewed, as will the potential incorporation of immunotherapy into treatment for sarcoma. RECENT FINDINGS: Sarcoma, cancer of the connective tissues, frequently strikes young people, comprising a large percentage of cancer in children and young adults, but may occur at any age. Although molecularly targeted inhibitors are of great interest in treating sarcoma patients, immunotherapy is emerging as a plausible therapeutic modality because of the recent advances in other cancer types that may be translated to sarcoma. The licensing of ipilimumab and sipuleucel-T for cancer, and the remarkable success of immunotherapy for some childhood cancers, suggest a role for immunotherapy in the treatment of tumors like sarcoma. SUMMARY: Sarcoma is a disease for which new treatments are needed. Immunotherapies have different mechanisms of action from most current therapies and could work in concert with them. Recent advances in sarcoma biology and cancer immunotherapy suggest that our knowledge of the immune system has reached the point where it can be used to augment both targeted and multimodality therapy for sarcoma.",
keywords = "antibody, cancer immunotherapy, cancer vaccines, dendritic cells, sarcoma",
author = "Goldberg, {John M.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1097/CCO.0b013e3283622c8a",
language = "English",
volume = "25",
pages = "390--397",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Immunotherapy of sarcomas

AU - Goldberg, John M.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - PURPOSE OF REVIEW: To describe the current advances in immunotherapy and how they can be applied to sarcoma. This review will discuss the recent literature and selected clinical trials. Evidence supporting treatment with immunotherapy alone in sarcoma will be reviewed, as will the potential incorporation of immunotherapy into treatment for sarcoma. RECENT FINDINGS: Sarcoma, cancer of the connective tissues, frequently strikes young people, comprising a large percentage of cancer in children and young adults, but may occur at any age. Although molecularly targeted inhibitors are of great interest in treating sarcoma patients, immunotherapy is emerging as a plausible therapeutic modality because of the recent advances in other cancer types that may be translated to sarcoma. The licensing of ipilimumab and sipuleucel-T for cancer, and the remarkable success of immunotherapy for some childhood cancers, suggest a role for immunotherapy in the treatment of tumors like sarcoma. SUMMARY: Sarcoma is a disease for which new treatments are needed. Immunotherapies have different mechanisms of action from most current therapies and could work in concert with them. Recent advances in sarcoma biology and cancer immunotherapy suggest that our knowledge of the immune system has reached the point where it can be used to augment both targeted and multimodality therapy for sarcoma.

AB - PURPOSE OF REVIEW: To describe the current advances in immunotherapy and how they can be applied to sarcoma. This review will discuss the recent literature and selected clinical trials. Evidence supporting treatment with immunotherapy alone in sarcoma will be reviewed, as will the potential incorporation of immunotherapy into treatment for sarcoma. RECENT FINDINGS: Sarcoma, cancer of the connective tissues, frequently strikes young people, comprising a large percentage of cancer in children and young adults, but may occur at any age. Although molecularly targeted inhibitors are of great interest in treating sarcoma patients, immunotherapy is emerging as a plausible therapeutic modality because of the recent advances in other cancer types that may be translated to sarcoma. The licensing of ipilimumab and sipuleucel-T for cancer, and the remarkable success of immunotherapy for some childhood cancers, suggest a role for immunotherapy in the treatment of tumors like sarcoma. SUMMARY: Sarcoma is a disease for which new treatments are needed. Immunotherapies have different mechanisms of action from most current therapies and could work in concert with them. Recent advances in sarcoma biology and cancer immunotherapy suggest that our knowledge of the immune system has reached the point where it can be used to augment both targeted and multimodality therapy for sarcoma.

KW - antibody

KW - cancer immunotherapy

KW - cancer vaccines

KW - dendritic cells

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84879884723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879884723&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e3283622c8a

DO - 10.1097/CCO.0b013e3283622c8a

M3 - Article

C2 - 23736878

AN - SCOPUS:84879884723

VL - 25

SP - 390

EP - 397

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -